Using CRISPR to Modulate Gene Expression

May 29, 2025

Epicrispr Biotechnologies is using CRISPR to modulate the expression of disease-causing genes without making cuts to DNA. Its lead program is in development to treat FSHD, a genetic disorder that causes progressive weakness in the muscles of the face, shoulders, and upper arms. We spoke to Amber Salzman, CEO of Epicrispr, about how its one-and-done therapies work to target the epigenome, the company’s lead program in FSHD, and the broader applications for its therapeutic approach.

Stay Connected

Facebook Twitter Instagram Youtube

Using CRISPR to Modulate Gene Expression

Related

FDA Grants Full Approval to Travere’s Filspari for FSGS

FDA Grants RMAT Designation to Grace Science’s Gene Therapy for NGLY1 Deficiency

Illumina Partners with D3b to Advance Genomic Research in Pediatric Rare Diseases

Labcorp and CHOP Collaborate to Improve Diagnosis of Pediatric Patients

FDA’s Makary Calls for Congress to Make Rare Pediatric Disease PRVs Permanent

From Treating Symptoms to Addressing Causes in Rare Autoimmune Diseases

Sarepta Reports Encouraging Clinical Data from siRNA Pipeline for FSHD1 and DM1

FDA Grants Fast Track Designation to Climb Bio’s Rare Kidney Disease Drug

Neurocrine to Buy Soleno for $2.9 Billion

Stay Connected